Thermo Fisher authorizes up to $5 billion of share repurchases

Thermo Fisher Scientific’s board approved a new share‑repurchase authorization of up to $5 billion, replacing the remaining $1 billion from the prior program. The authorization has no expiration date and may be executed in the open market or through negotiated transactions. The company reported annual revenue of $45 billion and highlighted strong cash generation in the nine months to September 26, 2026. The announcement coincided with third‑quarter earnings that beat expectations and an upward revision of fiscal‑2026 guidance.

The new $5 billion capacity gives the company flexibility to return cash to shareholders, potentially supporting the share price and dividend policy. It also adds a sizable discretionary use of cash alongside ongoing acquisition spending and debt service, as noted in the company’s nine‑month cash‑flow statement.

  • 1The board authorized repurchase of up to $5 billion of common stock with no expiration date.
  • 2The new authorization replaces a prior authorization that had $1 billion remaining.
  • 3Thermo Fisher reported annual revenue of approximately $45 billion.
  • 4Operating cash flow for the nine months ended September 26, 2026 was $5.867 billion.
  • 5Free cash flow for the same period was $4.618 billion.
  • 6Third‑quarter adjusted earnings were $6.68 per share and sales were $12.137 billion, both beating estimates.

Sources